UA62996C2 - 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines - Google Patents

Info

Publication number

UA62996C2

UA62996C2 UA2000095500A UA2000095500A UA62996C2 UA 62996 C2 UA62996 C2 UA 62996C2 UA 2000095500 A UA2000095500 A UA 2000095500A UA 2000095500 A UA2000095500 A UA 2000095500A UA 62996 C2 UA62996 C2 UA 62996C2

Authority

UA

Ukraine

Prior art keywords

amino

aminocyclohexyl

dihydrochloride

cyclopentylpurine

trans

Prior art date

1998-02-26

Links

• Espacenet
• Global Dossier
• Discuss

• -1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines Chemical class 0.000 title claims abstract description 72
• 150000001875 compounds Chemical class 0.000 claims abstract description 92
• 238000000034 method Methods 0.000 claims abstract description 48
• 150000003839 salts Chemical class 0.000 claims abstract description 27
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 24
• 230000003287 optical effect Effects 0.000 claims abstract description 24
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract description 23
• 150000004677 hydrates Chemical class 0.000 claims abstract description 23
• 125000001424 substituent group Chemical group 0.000 claims abstract description 21
• 230000006907 apoptotic process Effects 0.000 claims abstract description 20
• 239000001257 hydrogen Substances 0.000 claims abstract description 16
• 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
• 210000002569 neuron Anatomy 0.000 claims abstract description 15
• 239000000203 mixture Substances 0.000 claims abstract description 14
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 11
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 9
• 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 9
• 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 9
• 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract description 8
• 239000003937 drug carrier Substances 0.000 claims abstract description 8
• 125000002947 alkylene group Chemical group 0.000 claims abstract description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 188
• 201000000053 blastoma Diseases 0.000 claims description 85
• 201000008184 embryoma Diseases 0.000 claims description 85
• 210000004027 cell Anatomy 0.000 claims description 84
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 41
• 125000000217 alkyl group Chemical group 0.000 claims description 32
• 201000010099 disease Diseases 0.000 claims description 32
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 23
• 201000009030 Carcinoma Diseases 0.000 claims description 19
• 201000001441 melanoma Diseases 0.000 claims description 18
• 208000009956 adenocarcinoma Diseases 0.000 claims description 17
• 125000006308 propyl amino group Chemical group 0.000 claims description 17
• 208000032839 leukemia Diseases 0.000 claims description 16
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
• 239000002246 antineoplastic agent Substances 0.000 claims description 13
• 210000000481 breast Anatomy 0.000 claims description 13
• 206010039491 Sarcoma Diseases 0.000 claims description 12
• 210000001072 colon Anatomy 0.000 claims description 12
• 210000004072 lung Anatomy 0.000 claims description 12
• 210000000813 small intestine Anatomy 0.000 claims description 10
• 210000002307 prostate Anatomy 0.000 claims description 9
• 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
• 208000017604 Hodgkin disease Diseases 0.000 claims description 6
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
• 230000006378 damage Effects 0.000 claims description 6
• 201000008968 osteosarcoma Diseases 0.000 claims description 6
• 210000002784 stomach Anatomy 0.000 claims description 6
• 206010024612 Lipoma Diseases 0.000 claims description 5
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
• 210000001672 ovary Anatomy 0.000 claims description 5
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 4
• 201000011066 hemangioma Diseases 0.000 claims description 4
• 230000003463 hyperproliferative effect Effects 0.000 claims description 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
• 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
• 208000024207 chronic leukemia Diseases 0.000 claims description 3
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
• 210000003238 esophagus Anatomy 0.000 claims description 3
• 210000003739 neck Anatomy 0.000 claims description 3
• 230000019581 neuron apoptotic process Effects 0.000 claims description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
• 201000003076 Angiosarcoma Diseases 0.000 claims description 2
• 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
• 230000003325 follicular Effects 0.000 claims description 2
• 206010024627 liposarcoma Diseases 0.000 claims description 2
• 210000003563 lymphoid tissue Anatomy 0.000 claims description 2
• 230000000684 melanotic effect Effects 0.000 claims description 2
• 210000003660 reticulum Anatomy 0.000 claims description 2
• 229910052708 sodium Inorganic materials 0.000 claims description 2
• 210000002700 urine Anatomy 0.000 claims description 2
• MXJUOYXSYWPMAR-JVCDYITPSA-N (2s)-2-amino-n-[5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C[C@H](N)C(=O)NC1C(O)C(N2C3=NC=NC(=C3N=C2)N(C)C)OC1CO MXJUOYXSYWPMAR-JVCDYITPSA-N 0.000 claims 4
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
• 208000006431 amelanotic melanoma Diseases 0.000 claims 1
• 125000003118 aryl group Chemical group 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 abstract description 78
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
• 238000011161 development Methods 0.000 abstract description 11
• 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 168
• 108050006400 Cyclin Proteins 0.000 description 51
• 102000016736 Cyclin Human genes 0.000 description 50
• 108090000623 proteins and genes Proteins 0.000 description 36
• 241000282414 Homo sapiens Species 0.000 description 32
• TVGDBGPLYZULGD-UHFFFAOYSA-N 2,6-dichloro-9-cyclopentylpurine Chemical compound C12=NC(Cl)=NC(Cl)=C2N=CN1C1CCCC1 TVGDBGPLYZULGD-UHFFFAOYSA-N 0.000 description 29
• 230000003211 malignant effect Effects 0.000 description 24
• 238000004458 analytical method Methods 0.000 description 21
• 201000011510 cancer Diseases 0.000 description 20
• 108091000080 Phosphotransferase Proteins 0.000 description 18
• 102000020233 phosphotransferase Human genes 0.000 description 18
• 238000011282 treatment Methods 0.000 description 18
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
• 230000000694 effects Effects 0.000 description 17
• 210000001519 tissue Anatomy 0.000 description 17
• 235000018102 proteins Nutrition 0.000 description 16
• 102000004169 proteins and genes Human genes 0.000 description 16
• 208000026310 Breast neoplasm Diseases 0.000 description 14
• 230000011278 mitosis Effects 0.000 description 14
• 230000035772 mutation Effects 0.000 description 14
• 230000035755 proliferation Effects 0.000 description 14
• 210000004881 tumor cell Anatomy 0.000 description 14
• 206010006187 Breast cancer Diseases 0.000 description 13
• 108020004414 DNA Proteins 0.000 description 13
• 206010025323 Lymphomas Diseases 0.000 description 13
• 241000700605 Viruses Species 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
• 230000022131 cell cycle Effects 0.000 description 12
• 230000026731 phosphorylation Effects 0.000 description 12
• 238000006366 phosphorylation reaction Methods 0.000 description 12
• 239000000758 substrate Substances 0.000 description 12
• 229940088597 hormone Drugs 0.000 description 11
• 239000005556 hormone Substances 0.000 description 11
• 241000238631 Hexapoda Species 0.000 description 10
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 210000003491 skin Anatomy 0.000 description 10
• 206010027476 Metastases Diseases 0.000 description 9
• 102000001253 Protein Kinase Human genes 0.000 description 9
• 230000014509 gene expression Effects 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 108060006633 protein kinase Proteins 0.000 description 9
• 108090000257 Cyclin E Proteins 0.000 description 8
• 102000003909 Cyclin E Human genes 0.000 description 8
• 206010035226 Plasma cell myeloma Diseases 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 208000029742 colonic neoplasm Diseases 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 239000003814 drug Substances 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 210000003734 kidney Anatomy 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 206010041823 squamous cell carcinoma Diseases 0.000 description 8
• 208000011580 syndromic disease Diseases 0.000 description 8
• RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 7
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 7
• 108010068237 Cyclin H Proteins 0.000 description 7
• 102100036883 Cyclin-H Human genes 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 229940127093 camptothecin Drugs 0.000 description 7
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 7
• 239000002775 capsule Substances 0.000 description 7
• 230000032823 cell division Effects 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 7
• GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 7
• 210000000056 organ Anatomy 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 238000001356 surgical procedure Methods 0.000 description 7
• 230000002889 sympathetic effect Effects 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• 208000034578 Multiple myelomas Diseases 0.000 description 6
• 208000014767 Myeloproliferative disease Diseases 0.000 description 6
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
• 230000000259 anti-tumor effect Effects 0.000 description 6
• UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 6
• 239000004062 cytokinin Substances 0.000 description 6
• 230000034994 death Effects 0.000 description 6
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 208000020816 lung neoplasm Diseases 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 206010000830 Acute leukaemia Diseases 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 208000011691 Burkitt lymphomas Diseases 0.000 description 5
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 5
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 5
• 102000014150 Interferons Human genes 0.000 description 5
• 108010050904 Interferons Proteins 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 101100309443 Mus musculus Sacs gene Proteins 0.000 description 5
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 description 5
• 241000159610 Roya <green alga> Species 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 5
• 229950010817 alvocidib Drugs 0.000 description 5
• 229940041181 antineoplastic drug Drugs 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 102000015694 estrogen receptors Human genes 0.000 description 5
• 108010038795 estrogen receptors Proteins 0.000 description 5
• 201000004108 hypersplenism Diseases 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 206010028537 myelofibrosis Diseases 0.000 description 5
• 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• XDKPTYKTFBDFFM-UHFFFAOYSA-N 9-cyclopentylpurine Chemical compound C1CCCC1N1C2=NC=NC=C2N=C1 XDKPTYKTFBDFFM-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 108091007914 CDKs Proteins 0.000 description 4
• 102000005483 Cell Cycle Proteins Human genes 0.000 description 4
• 108010031896 Cell Cycle Proteins Proteins 0.000 description 4
• 108010060385 Cyclin B1 Proteins 0.000 description 4
• 230000006820 DNA synthesis Effects 0.000 description 4
• 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 4
• 206010018338 Glioma Diseases 0.000 description 4
• 102100034343 Integrase Human genes 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 241000208125 Nicotiana Species 0.000 description 4
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 150000001413 amino acids Chemical class 0.000 description 4
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
• 239000003183 carcinogenic agent Substances 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 210000000349 chromosome Anatomy 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 210000003128 head Anatomy 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 238000000021 kinase assay Methods 0.000 description 4
• 210000005053 lamin Anatomy 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 230000036210 malignancy Effects 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 230000031864 metaphase Effects 0.000 description 4
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 4
• 201000005962 mycosis fungoides Diseases 0.000 description 4
• 230000002018 overexpression Effects 0.000 description 4
• 210000004180 plasmocyte Anatomy 0.000 description 4
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 4
• 150000003254 radicals Chemical class 0.000 description 4
• 210000000664 rectum Anatomy 0.000 description 4
• 230000022983 regulation of cell cycle Effects 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 230000000284 resting effect Effects 0.000 description 4
• 239000011775 sodium fluoride Substances 0.000 description 4
• 235000013024 sodium fluoride Nutrition 0.000 description 4
• 210000000278 spinal cord Anatomy 0.000 description 4
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• CFTPMBWYBDKGSA-UHFFFAOYSA-N 2-cyclopentyl-7h-purine Chemical compound C1CCCC1C1=NC=C(NC=N2)C2=N1 CFTPMBWYBDKGSA-UHFFFAOYSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 108010085238 Actins Proteins 0.000 description 3
• 102000007469 Actins Human genes 0.000 description 3
• 206010004146 Basal cell carcinoma Diseases 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 108010068192 Cyclin A Proteins 0.000 description 3
• 102000002427 Cyclin B Human genes 0.000 description 3
• 108010068150 Cyclin B Proteins 0.000 description 3
• 102100025191 Cyclin-A2 Human genes 0.000 description 3
• 102100021906 Cyclin-O Human genes 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 206010014759 Endometrial neoplasm Diseases 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 201000008808 Fibrosarcoma Diseases 0.000 description 3
• 229940123414 Folate antagonist Drugs 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 235000010469 Glycine max Nutrition 0.000 description 3
• 108010033040 Histones Proteins 0.000 description 3
• 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 3
• 102000006835 Lamins Human genes 0.000 description 3
• 108010047294 Lamins Proteins 0.000 description 3
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 208000037062 Polyps Diseases 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 102000009572 RNA Polymerase II Human genes 0.000 description 3
• 108010009460 RNA Polymerase II Proteins 0.000 description 3
• 208000015634 Rectal Neoplasms Diseases 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 229930013930 alkaloid Natural products 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 150000001723 carbon free-radicals Chemical class 0.000 description 3
• 231100000357 carcinogen Toxicity 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000004186 co-expression Effects 0.000 description 3
• 201000010897 colon adenocarcinoma Diseases 0.000 description 3
• 210000003792 cranial nerve Anatomy 0.000 description 3
• VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 230000030609 dephosphorylation Effects 0.000 description 3
• 238000006209 dephosphorylation reaction Methods 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 238000009261 endocrine therapy Methods 0.000 description 3
• 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 3
• 229940011871 estrogen Drugs 0.000 description 3
• 239000000262 estrogen Substances 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 208000035474 group of disease Diseases 0.000 description 3
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
• 230000002779 inactivation Effects 0.000 description 3
• 229940079322 interferon Drugs 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 201000010260 leiomyoma Diseases 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 201000000564 macroglobulinemia Diseases 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 230000037353 metabolic pathway Effects 0.000 description 3
• 210000003632 microfilament Anatomy 0.000 description 3
• 230000000394 mitotic effect Effects 0.000 description 3
• PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 208000028591 pheochromocytoma Diseases 0.000 description 3
• 229940080469 phosphocellulose Drugs 0.000 description 3
• 235000011007 phosphoric acid Nutrition 0.000 description 3
• 210000003635 pituitary gland Anatomy 0.000 description 3
• 208000003476 primary myelofibrosis Diseases 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 239000000186 progesterone Substances 0.000 description 3
• 229960003387 progesterone Drugs 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 230000008521 reorganization Effects 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 229960001603 tamoxifen Drugs 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 2
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
• 125000006017 1-propenyl group Chemical group 0.000 description 2
• WRBOUHHLUAHREC-UHFFFAOYSA-N 2,8-dichloro-9-cyclopentylpurine Chemical compound ClC1=NC2=CN=C(Cl)N=C2N1C1CCCC1 WRBOUHHLUAHREC-UHFFFAOYSA-N 0.000 description 2
• WOQKMUDQRKXVLO-UHFFFAOYSA-N 2-[[7-methyl-6-[(phenylmethyl)amino]-2-purinyl]amino]ethanol Chemical compound C=12N(C)C=NC2=NC(NCCO)=NC=1NCC1=CC=CC=C1 WOQKMUDQRKXVLO-UHFFFAOYSA-N 0.000 description 2
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
• AAVVCMCCIQNHJC-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-propylpurin-6-amine Chemical compound C1=NC=2C(NCCC)=NC(Cl)=NC=2N1C1CCCC1 AAVVCMCCIQNHJC-UHFFFAOYSA-N 0.000 description 2
• 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 2
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
• 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 2
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
• 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• 108010043137 Actomyosin Proteins 0.000 description 2
• 108091093088 Amplicon Proteins 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 102000015790 Asparaginase Human genes 0.000 description 2
• 108010024976 Asparaginase Proteins 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 206010007270 Carcinoid syndrome Diseases 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 101100411591 Dictyostelium discoideum rab8B gene Proteins 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
• 229930182566 Gentamicin Natural products 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 206010053759 Growth retardation Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 206010062767 Hypophysitis Diseases 0.000 description 2
• 206010061216 Infarction Diseases 0.000 description 2
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 208000003445 Mouth Neoplasms Diseases 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 108060008487 Myosin Proteins 0.000 description 2
• 102000003505 Myosin Human genes 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
• 208000000035 Osteochondroma Diseases 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 208000002774 Paraproteinemias Diseases 0.000 description 2
• 208000009077 Pigmented Nevus Diseases 0.000 description 2
• 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• 208000035977 Rare disease Diseases 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000044159 Ubiquitin Human genes 0.000 description 2
• 108090000848 Ubiquitin Proteins 0.000 description 2
• 201000003761 Vaginal carcinoma Diseases 0.000 description 2
• 102100035071 Vimentin Human genes 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 210000000436 anus Anatomy 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000012062 aqueous buffer Substances 0.000 description 2
• 239000010425 asbestos Substances 0.000 description 2
• 229960003272 asparaginase Drugs 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 201000007327 bone benign neoplasm Diseases 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 201000008274 breast adenocarcinoma Diseases 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 238000001516 cell proliferation assay Methods 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 235000015218 chewing gum Nutrition 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
• XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 2
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 238000002224 dissection Methods 0.000 description 2
• 210000001198 duodenum Anatomy 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 230000000925 erythroid effect Effects 0.000 description 2
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 210000001508 eye Anatomy 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 201000004098 fibrolamellar carcinoma Diseases 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 229960002074 flutamide Drugs 0.000 description 2
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
• 229960002518 gentamicin Drugs 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 210000002288 golgi apparatus Anatomy 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 230000006951 hyperphosphorylation Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000007574 infarction Effects 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 210000004324 lymphatic system Anatomy 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• NSQQTIIWZCVMRW-UHFFFAOYSA-N n-benzyl-2-chloro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(Cl)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CC=C1 NSQQTIIWZCVMRW-UHFFFAOYSA-N 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• RELUKSSWENGPFT-UHFFFAOYSA-N n-butyl-2-chloro-9-cyclopentylpurin-6-amine Chemical compound C1=NC=2C(NCCCC)=NC(Cl)=NC=2N1C1CCCC1 RELUKSSWENGPFT-UHFFFAOYSA-N 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 230000009223 neuronal apoptosis Effects 0.000 description 2
• 230000003961 neuronal insult Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 238000011580 nude mouse model Methods 0.000 description 2
• 231100000590 oncogenic Toxicity 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 210000002990 parathyroid gland Anatomy 0.000 description 2
• DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 210000004560 pineal gland Anatomy 0.000 description 2
• 230000001817 pituitary effect Effects 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 239000000649 purine antagonist Substances 0.000 description 2
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
• 239000003790 pyrimidine antagonist Substances 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 206010038038 rectal cancer Diseases 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 229910052895 riebeckite Inorganic materials 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 230000000391 smoking effect Effects 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000001573 trophoblastic effect Effects 0.000 description 2
• APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
• 210000003905 vulva Anatomy 0.000 description 2
• 235000012431 wafers Nutrition 0.000 description 2
• 229910052727 yttrium Inorganic materials 0.000 description 2
• SJUKJZSTBBSGHF-UHFFFAOYSA-N (2,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1Cl SJUKJZSTBBSGHF-UHFFFAOYSA-N 0.000 description 1
• KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 1
• LRFWYBZWRQWZIM-UHFFFAOYSA-N (2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC=C1F LRFWYBZWRQWZIM-UHFFFAOYSA-N 0.000 description 1
• IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 1
• LQLOGZQVKUNBRX-UHFFFAOYSA-N (3-iodophenyl)methanamine Chemical compound NCC1=CC=CC(I)=C1 LQLOGZQVKUNBRX-UHFFFAOYSA-N 0.000 description 1
• RGXUCUWVGKLACF-UHFFFAOYSA-N (3-methylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 description 1
• ODMMHGMIZYLHNN-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1F ODMMHGMIZYLHNN-UHFFFAOYSA-N 0.000 description 1
• YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
• IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• 101150084750 1 gene Proteins 0.000 description 1
• 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
• PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 description 1
• BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
• RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
• PYVRVRFVLRNJLY-KTKRTIGZSA-N 1-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COP(O)(=O)OCCN PYVRVRFVLRNJLY-KTKRTIGZSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• OPMFFAOEPFATTG-UHFFFAOYSA-N 2,2,2-trifluoroethylhydrazine Chemical compound NNCC(F)(F)F OPMFFAOEPFATTG-UHFFFAOYSA-N 0.000 description 1
• GKEFDRUWUYSFGW-UHFFFAOYSA-N 2,6-dichloro-9-propan-2-ylpurine Chemical compound N1=C(Cl)N=C2N(C(C)C)C=NC2=C1Cl GKEFDRUWUYSFGW-UHFFFAOYSA-N 0.000 description 1
• OKZKXXPXTKWQAG-UHFFFAOYSA-N 2,6-dichloro-9-propan-2-ylpurine Chemical compound ClC1=NC(=C2N=CN(C2=N1)C(C)C)Cl.ClC1=NC(=C2N=CN(C2=N1)C(C)C)Cl OKZKXXPXTKWQAG-UHFFFAOYSA-N 0.000 description 1
• DHPOUEPMENIWGX-UHFFFAOYSA-N 2-(aminomethyl)butan-1-ol Chemical compound CCC(CN)CO DHPOUEPMENIWGX-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
• DMFKUKKGUQYKLL-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-(4-phenylbutyl)purin-6-amine Chemical compound C=12N=CN(C3CCCC3)C2=NC(Cl)=NC=1NCCCCC1=CC=CC=C1 DMFKUKKGUQYKLL-UHFFFAOYSA-N 0.000 description 1
• OIUGUEQFWXNSPR-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-ethylpurin-6-amine Chemical compound C1=NC=2C(NCC)=NC(Cl)=NC=2N1C1CCCC1 OIUGUEQFWXNSPR-UHFFFAOYSA-N 0.000 description 1
• LHZHRAFIWBWVHJ-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-hexylpurin-6-amine Chemical compound C1=NC=2C(NCCCCCC)=NC(Cl)=NC=2N1C1CCCC1 LHZHRAFIWBWVHJ-UHFFFAOYSA-N 0.000 description 1
• IKYTXKJDCDIVTJ-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-methylpurin-6-amine Chemical compound C1=NC=2C(NC)=NC(Cl)=NC=2N1C1CCCC1 IKYTXKJDCDIVTJ-UHFFFAOYSA-N 0.000 description 1
• VIVHSNXBTRADQA-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-octylpurin-6-amine Chemical compound C1=NC=2C(NCCCCCCCC)=NC(Cl)=NC=2N1C1CCCC1 VIVHSNXBTRADQA-UHFFFAOYSA-N 0.000 description 1
• PWPRDQIWZVWOQX-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-n-pentylpurin-6-amine Chemical compound C1=NC=2C(NCCCCC)=NC(Cl)=NC=2N1C1CCCC1 PWPRDQIWZVWOQX-UHFFFAOYSA-N 0.000 description 1
• 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
• HQNOODJDSFSURF-UHFFFAOYSA-N 3-(1h-imidazol-2-yl)propan-1-amine Chemical compound NCCCC1=NC=CN1 HQNOODJDSFSURF-UHFFFAOYSA-N 0.000 description 1
• KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
• 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 description 1
• 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
• UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 1
• LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
• 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 1
• LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 102100032187 Androgen receptor Human genes 0.000 description 1
• 102000008102 Ankyrins Human genes 0.000 description 1
• 108010049777 Ankyrins Proteins 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 241001565477 Aphyosemion omega Species 0.000 description 1
• 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
• 101100023997 Caenorhabditis elegans mom-2 gene Proteins 0.000 description 1
• 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
• 102000000584 Calmodulin Human genes 0.000 description 1
• 108010041952 Calmodulin Proteins 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 201000005262 Chondroma Diseases 0.000 description 1
• 208000010126 Chondromatosis Diseases 0.000 description 1
• 208000019591 Chondromyxoid fibroma Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 235000003913 Coccoloba uvifera Nutrition 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 206010011703 Cyanosis Diseases 0.000 description 1
• 102000008179 Cyclin B2 Human genes 0.000 description 1
• 108010060387 Cyclin B2 Proteins 0.000 description 1
• 102000002428 Cyclin C Human genes 0.000 description 1
• 108010068155 Cyclin C Proteins 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 102100024106 Cyclin-Y Human genes 0.000 description 1
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
• 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
• 101710106276 Cyclin-dependent kinase 7 Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 102000004214 DNA polymerase A Human genes 0.000 description 1
• 108090000725 DNA polymerase A Proteins 0.000 description 1
• 231100001074 DNA strand break Toxicity 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 208000001154 Dermoid Cyst Diseases 0.000 description 1
• 102100036912 Desmin Human genes 0.000 description 1
• 108010044052 Desmin Proteins 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 201000010374 Down Syndrome Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
• 208000017701 Endocrine disease Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 206010073306 Exposure to radiation Diseases 0.000 description 1
• 201000004939 Fanconi anemia Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 206010017076 Fracture Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 208000000527 Germinoma Diseases 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• 244000194101 Ginkgo biloba Species 0.000 description 1
• 235000008100 Ginkgo biloba Nutrition 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 241000989913 Gunnera petaloidea Species 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 206010019629 Hepatic adenoma Diseases 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000910602 Homo sapiens Cyclin-Y Proteins 0.000 description 1
• 101000715942 Homo sapiens Cyclin-dependent kinase 4 Proteins 0.000 description 1
• 101000713023 Homo sapiens G2/mitotic-specific cyclin-B2 Proteins 0.000 description 1
• 101001072338 Homo sapiens Proliferating cell nuclear antigen Proteins 0.000 description 1
• 101000693611 Homo sapiens Serine/threonine-protein kinase SBK2 Proteins 0.000 description 1
• 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• 108010003272 Hyaluronate lyase Proteins 0.000 description 1
• 206010060377 Hypergastrinaemia Diseases 0.000 description 1
• 201000002980 Hyperparathyroidism Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 101710172804 K protein Proteins 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 206010069930 Lacrimal haemorrhage Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
• 208000007369 Malignant Mixed Tumor Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
• 206010027145 Melanocytic naevus Diseases 0.000 description 1
• 101000844611 Metallosphaera sedula (strain ATCC 51363 / DSM 5348 / JCM 9185 / NBRC 15509 / TH2) DNA-binding protein 7 Proteins 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
• 102000002151 Microfilament Proteins Human genes 0.000 description 1
• 108010040897 Microfilament Proteins Proteins 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 241000700560 Molluscum contagiosum virus Species 0.000 description 1
• 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
• 241001206439 Motya Species 0.000 description 1
• 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
• 102000005640 Myosin Type II Human genes 0.000 description 1
• 108010045128 Myosin Type II Proteins 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 108700019961 Neoplasm Genes Proteins 0.000 description 1
• 102000048850 Neoplasm Genes Human genes 0.000 description 1
• 206010056677 Nerve degeneration Diseases 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 101710155723 Non-muscle caldesmon Proteins 0.000 description 1
• 108020004485 Nonsense Codon Proteins 0.000 description 1
• 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
• 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 206010073338 Optic glioma Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 208000003076 Osteolysis Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000027067 Paget disease of bone Diseases 0.000 description 1
• 208000025618 Paget disease of nipple Diseases 0.000 description 1
• 208000024024 Paget disease of the nipple Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 241001311547 Patina Species 0.000 description 1
• 102000015731 Peptide Hormones Human genes 0.000 description 1
• 108010038988 Peptide Hormones Proteins 0.000 description 1
• 241001387976 Pera Species 0.000 description 1
• RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
• BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 201000005746 Pituitary adenoma Diseases 0.000 description 1
• 206010061538 Pituitary tumour benign Diseases 0.000 description 1
• 208000020424 Polyglandular disease Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000007541 Preleukemia Diseases 0.000 description 1
• 102100025803 Progesterone receptor Human genes 0.000 description 1
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
• WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 206010056626 Pseudopolyp Diseases 0.000 description 1
• 240000008976 Pterocarpus marsupium Species 0.000 description 1
• 239000005700 Putrescine Substances 0.000 description 1
• 102000017143 RNA Polymerase I Human genes 0.000 description 1
• 108010013845 RNA Polymerase I Proteins 0.000 description 1
• 241000773293 Rappaport Species 0.000 description 1
• 101000836455 Rattus norvegicus Aldo-keto reductase family 1 member B1 Proteins 0.000 description 1
• 101000809448 Rattus norvegicus Amphiregulin Proteins 0.000 description 1
• 101000928257 Rattus norvegicus NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 206010038074 Rectal polyp Diseases 0.000 description 1
• 208000009527 Refractory anemia Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 108050002653 Retinoblastoma protein Proteins 0.000 description 1
• 241000220317 Rosa Species 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 102100025559 Serine/threonine-protein kinase SBK2 Human genes 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010040860 Skin haemorrhages Diseases 0.000 description 1
• 206010041660 Splenomegaly Diseases 0.000 description 1
• 235000018087 Spondias lutea Nutrition 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
• 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
• 241000388430 Tara Species 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000005485 Thrombocytosis Diseases 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 102000005497 Thymidylate Synthase Human genes 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 206010046798 Uterine leiomyoma Diseases 0.000 description 1
• 208000009311 VIPoma Diseases 0.000 description 1
• 108010065472 Vimentin Proteins 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000863480 Vinca Species 0.000 description 1
• BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 206010048211 Xanthelasma Diseases 0.000 description 1
• 206010048214 Xanthoma Diseases 0.000 description 1
• 206010048215 Xanthomatosis Diseases 0.000 description 1
• 241001377938 Yara Species 0.000 description 1
• FPVUCBMBMUHRDX-XMMPIXPASA-N [4-hydroxy-3-(3-methylbut-2-enyl)phenyl]methyl (2r)-4-hydroxy-3-(4-hydroxyphenyl)-2-methyl-5-oxofuran-2-carboxylate Chemical compound C1=C(O)C(CC=C(C)C)=CC(COC(=O)[C@@]2(C)C(=C(O)C(=O)O2)C=2C=CC(O)=CC=2)=C1 FPVUCBMBMUHRDX-XMMPIXPASA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
• 210000001943 adrenal medulla Anatomy 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000031016 anaphase Effects 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 108010080146 androgen receptors Proteins 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 239000000010 aprotic solvent Substances 0.000 description 1
• 229910052785 arsenic Inorganic materials 0.000 description 1
• RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
• 230000005744 arteriovenous malformation Effects 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 230000008033 biological extinction Effects 0.000 description 1
• HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical class ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 description 1
• 210000003969 blast cell Anatomy 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 208000016738 bone Paget disease Diseases 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 201000005389 breast carcinoma in situ Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 102000028861 calmodulin binding Human genes 0.000 description 1
• 108091000084 calmodulin binding Proteins 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 208000022033 carcinoma of urethra Diseases 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000018486 cell cycle phase Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 201000004226 ceruminoma Diseases 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
• 229940112822 chewing gum Drugs 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 201000005217 chondroblastoma Diseases 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical class [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
• 230000010428 chromatin condensation Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 210000003618 cortical neuron Anatomy 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• AVKNGPAMCBSNSO-UHFFFAOYSA-N cyclohexylmethanamine Chemical compound NCC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-N 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000000093 cytochemical effect Effects 0.000 description 1
• 230000021953 cytokinesis Effects 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 208000024389 cytopenia Diseases 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 210000005045 desmin Anatomy 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 210000004921 distal colon Anatomy 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 210000000613 ear canal Anatomy 0.000 description 1
• 210000000883 ear external Anatomy 0.000 description 1
• 210000000959 ear middle Anatomy 0.000 description 1
• 201000003511 ectopic pregnancy Diseases 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 201000011523 endocrine gland cancer Diseases 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003059 ependyma Anatomy 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
• 201000000497 familial melanoma Diseases 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 230000008713 feedback mechanism Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 230000006650 fundamental cellular process Effects 0.000 description 1
• DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 201000003115 germ cell cancer Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 201000001505 hemoglobinuria Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 201000002735 hepatocellular adenoma Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000002363 herbicidal effect Effects 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 102000054528 human CCNB2 Human genes 0.000 description 1
• 102000048992 human CDK4 Human genes 0.000 description 1
• PYFDZOCGFHIRST-UHFFFAOYSA-N hydron;(3-iodophenyl)methanamine;chloride Chemical compound Cl.NCC1=CC=CC(I)=C1 PYFDZOCGFHIRST-UHFFFAOYSA-N 0.000 description 1
• ZTUJDPKOHPKRMO-UHFFFAOYSA-N hydron;2,2,2-trifluoroethanamine;chloride Chemical compound Cl.NCC(F)(F)F ZTUJDPKOHPKRMO-UHFFFAOYSA-N 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 208000017819 hyperplastic polyp Diseases 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 238000013383 initial experiment Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910001410 inorganic ion Inorganic materials 0.000 description 1
• 239000002198 insoluble material Substances 0.000 description 1
• 238000009413 insulation Methods 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• 208000020123 juvenile polyp Diseases 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000000244 kidney pelvis Anatomy 0.000 description 1
• 244000145841 kine Species 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 201000011059 lobular neoplasia Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 201000001142 lung small cell carcinoma Diseases 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 230000001589 lymphoproliferative effect Effects 0.000 description 1
• 208000025036 lymphosarcoma Diseases 0.000 description 1
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 201000002742 malignant choroid melanoma Diseases 0.000 description 1
• 201000004593 malignant giant cell tumor Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 210000004175 meibomian gland Anatomy 0.000 description 1
• 210000002752 melanocyte Anatomy 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000009245 menopause Effects 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
• 229910052753 mercury Inorganic materials 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
• RRIRDPSOCUCGBV-UHFFFAOYSA-N methylenedioxyphenethylamine Chemical compound NCCC1=CC=C2OCOC2=C1 RRIRDPSOCUCGBV-UHFFFAOYSA-N 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 208000008588 molluscum contagiosum Diseases 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 201000003428 multiple mucosal neuroma Diseases 0.000 description 1
• 208000033937 musculocontractural type Ehlers-Danlos syndrome Diseases 0.000 description 1
• 230000002071 myeloproliferative effect Effects 0.000 description 1
• RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
• CXGFWBPQQXZELI-UHFFFAOYSA-N n-ethylpyridin-2-amine Chemical compound CCNC1=CC=CC=N1 CXGFWBPQQXZELI-UHFFFAOYSA-N 0.000 description 1
• JNHZPXFARRJZQR-UHFFFAOYSA-N n-ethylpyridin-3-amine Chemical compound CCNC1=CC=CN=C1 JNHZPXFARRJZQR-UHFFFAOYSA-N 0.000 description 1
• OTIDWUALRXXVIM-UHFFFAOYSA-N n-ethylpyridin-4-amine Chemical compound CCNC1=CC=NC=C1 OTIDWUALRXXVIM-UHFFFAOYSA-N 0.000 description 1
• ALBBQFWHUCTZFM-UHFFFAOYSA-N n-methyl-1h-benzimidazol-2-amine Chemical compound C1=CC=C2NC(NC)=NC2=C1 ALBBQFWHUCTZFM-UHFFFAOYSA-N 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 230000008271 nervous system development Effects 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000016273 neuron death Effects 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 230000037434 nonsense mutation Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• 210000002353 nuclear lamina Anatomy 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 208000008511 optic nerve glioma Diseases 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 108010036550 osteoclast activating factor Proteins 0.000 description 1
• 208000003388 osteoid osteoma Diseases 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• NYGCBQKDTGBHSC-UHFFFAOYSA-N oxan-2-ylmethanamine Chemical compound NCC1CCCCO1 NYGCBQKDTGBHSC-UHFFFAOYSA-N 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 208000007312 paraganglioma Diseases 0.000 description 1
• 210000003695 paranasal sinus Anatomy 0.000 description 1
• 230000001314 paroxysmal effect Effects 0.000 description 1
• 235000015927 pasta Nutrition 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 208000030940 penile carcinoma Diseases 0.000 description 1
• 201000008174 penis carcinoma Diseases 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 229940100684 pentylamine Drugs 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 229960000964 phenelzine Drugs 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000000865 phosphorylative effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 208000021310 pituitary gland adenoma Diseases 0.000 description 1
• 239000005648 plant growth regulator Substances 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 208000014081 polyp of colon Diseases 0.000 description 1
• 208000022075 polyp of rectum Diseases 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 210000002729 polyribosome Anatomy 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108090000468 progesterone receptors Proteins 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 230000006825 purine synthesis Effects 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 230000006824 pyrimidine synthesis Effects 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 201000010174 renal carcinoma Diseases 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000003307 reticuloendothelial effect Effects 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 229940016590 sarkosyl Drugs 0.000 description 1
• 108700004121 sarkosyl Proteins 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 210000001599 sigmoid colon Anatomy 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
• 229940127198 soluble adenylyl cyclase inhibitor Drugs 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 230000020347 spindle assembly Effects 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000010911 splenectomy Methods 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
• 230000036561 sun exposure Effects 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 210000003582 temporal bone Anatomy 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 235000019505 tobacco product Nutrition 0.000 description 1
• 239000002341 toxic gas Substances 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000017105 transposition Effects 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 150000003628 tricarboxylic acids Chemical class 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
• 230000001228 trophic effect Effects 0.000 description 1
• 208000022271 tubular adenoma Diseases 0.000 description 1
• 208000022158 tubulovillous adenoma Diseases 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 229960003732 tyramine Drugs 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 208000009540 villous adenoma Diseases 0.000 description 1
• 210000005048 vimentin Anatomy 0.000 description 1
• HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1